Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma

British Journal of Haematology

Volumn 130, Issue 4, 2005, Pages 536-541

  Burton, C ^b   Smith, P ^b   Vaughan Hudson, G ^b   Qian, W ^c   Hoskin, P ^d   Cunningham, D ^e   Hancock, B ^f   Linch, D ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

^d MOUNT VERNON HOSPITAL   (United Kingdom)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

CHOP; CIOP; Histologically aggressive; Idarubicin; Non Hodgkin lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; IDARUBICIN; METHOTREXATE; PREDNISOLONE; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; CIOP PROTOCOL; PREDNISONE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PARANASAL SINUS DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TESTIS DISEASE; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; REMISSION; TREATMENT FAILURE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHI-SQUARE DISTRIBUTION; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; IDARUBICIN; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDNISOLONE; PREDNISONE; PROGNOSIS; REMISSION INDUCTION; TREATMENT FAILURE; VINCRISTINE;

EID: 24944557222     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05640.x     Document Type: Article

References (21)

1. Berman E. McBride M. ( 1992) Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukaemia cells. Blood, 79, 3267 3273.
2. Bertelli G. Amoroso D. Pronzato P. Rosso R. ( 1988) Idarubicin: an evaluation of cardiac toxicity in 77 patients with solid tumors. Anticancer Research, 8, 645 646.
3. Bertini M. Freilone R. Botto B. Calvi R. Gallamini A. Gatti A. Liberati A. Meneghini V. Orlandi E. Orsucci L. Pizzuti M. Scalabrini D. Salvi F. Todeschini G. Vitolo U. Resegotti L. ( 1997) Idarubicin in patients with diffuse large cell lymphomas: a randomised trial comparing VACOP-B (A = doxorubicin) vs VICOP-B (I = idarubicin). Haematologica, 82, 309 313.
4. Coiffier B. Lepage E. Briere J. Herbrecht R. Tilly H. Bouabdallah R. Morel P. Van Den Neste E. Salles G. Gaulard P. Reyes F. Lederlin P. Gisselbrecht C. ( 2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235 242.
5. Cook G. Clark R.E. Morris T.C. Robertson M. Lucie N.P. Anderson S. Paul J. Franklin I.M. ( 2004) A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma. British Journal of Haematology, 126, 792 798.
6. Fisher R.I. Gaynor E.R. Dahlberg S. Oken M.M. Grogan T.M. Mize E.M. Glick J.H. Coltman C.A. Jr. Miller T.P. ( 1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New England Journal of Medicine, 328, 1002 1006.
7. Kaplan E.L. Meier P. ( 1958) Non parametric estimation from incomplete observations. Journal of American Statistical Association, 53, 457 481.
8. Kroschinsky F. Schleyer E. Renner U. Schimming C. Schimmelpfennig C. Bornhauser M. Illmer T. Trumper L. Ehninger G. Schaich M. ( 2004) Increased myelotoxicity of idarubicin: is there a pharmacological basis? Cancer Chemotherapy Pharmacology, 53, 61 67.
9. Martoni A. Piana E. Guaraldi M. Cilenti G. Farris A. Saccani F. Becchi G. Pannuti F. ( 1990) Comparative phase II study of idarubicin versus doxorubicin in advanced breast cancer. Oncology, 47, 427 432.
10. McKelvey E.M. Gottlieb J.A. Wilson H.E. Haut A. Talley R.W. Stephens R. Lane M. Gamble J.F. Jones S.E. Grozea P.N. Gutterman J. Coltman C. Moon T.E. ( 1976) Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer, 38, 1484 1493.
11. Miller T.P. Grogan T.M. Dalton W.S. Spier C.M. Scheper R.J. Salmon S.E. ( 1991) P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. Journal Of Clinical Oncology, 9, 17 24.
12. Moreton P. Morgan G. Gilson D. Smith G. McVerry B. Davies J. Mackie M. Bolam S. Jalihal S. Howard M. Parapia L. Williams A. Child J., Central and Southern Lymphoma Group ( 2004) The development of targeted chemotherapy for CNS lymphoma-a pilot study of the IDARAM regimen. Cancer Chemotherapy Pharmacology, 53, 324 328.
13. Pfreundschuh M. Trumper L. Gill D. Osterborg A. Pettengell R. Trneny M. Imrie K. Walewski J. Zinzani P.-L. Loeffler M. ( 2004) First analysis of the completed MabThera international (MInT) trial in young patients with low-risk diffuse large B-cell lymphoma (DLBCL): Addition of rituximab to a CHOP-like regimen significantly improves outcome of all patients with the identification of a very favourable subgroup with IPI = 0 and no bulky disease. Blood, 104, abstract 157.
14. Reid J. Pendergrass T. Krailo M. Hammond G. Ames M. ( 1990) Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukaemia patients: a children's cancer study group report. Cancer Research, 50, 6525 6528.
15. Shipp M. Harrington D. Andersen J. ( 1993) A predictive model for aggressive non-Hodgkin's lymphoma. The international non-Hodgkin lymphoma prognostic factors project. New England Journal of Medicine, 329, 987 994.
16. Sonneveld P. ( 2000) Multidrug resistance in haematological malignancies. Journal of Internal Medicine, 247, 521 534.
17. Trumper L. Kloess M. Schmits R. Kaiser U. Engert A. Reiser M. Hoffkes H. Kroschinsky F. Mesters M. Feller A. Loffler M. Pfreundschuh M. ( 2002) Significant dose escalation of idarubicin in the treatment of aggressive non-Hodgkin's lymphoma leads to increased hematoxicity without improvement of efficacy: final resuts of a phase I/II trail of the German high grade NHL study group (DSHNHL). Annals of Oncology, 13 ( Suppl. 2 abstract 548.
18. Tulpule A. Sherrod A. Dharmapala D. Young L.L. Espina B.M. Sanchez M.N. Gill P.S. Levine A.M. ( 2002) Multidrug resistance (MDR-1) expression in AIDS-related lymphomas. Leukaemia Research, 26, 121 127.
19. Villani F. Galimberti M. Comazzi R. Crippa F. ( 1989) Evaluation of cardiac toxicity of idarubicin. European Journal of Cancer and Clinical Oncology, 25, 13 18.
20. Yuen A.R. Sikic B.I. ( 1994) Multidrug resistance in lymphomas. Journal of Clinical Oncology, 12, 2453 2459.
21. Zinzani P. Martelli M. Storti S. Musso M. Cantonetti M. Leone G. Cajozzo A. Papa G. Iannitto E. Perrotti A. ( 1995) Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate grade non-Hodgkin's lymphoma. Leukaemia Lymphoma, 19, 329 333.